Cartalax (25mg)

Cartalax (25mg): Product Description

Cartalax is a synthetic short-chain bioregulatory peptide composed of alanine, glutamic acid and aspartic acid. Its three-amino-acid sequence, Ala-Glu-Asp, makes it a tripeptide suitable for controlled studies of short regulatory peptides and their interactions with cartilage- and connective-tissue-related cellular systems.

Laboratory investigations may examine Cartalax in relation to extracellular-matrix signaling, chondrocyte-associated processes, cellular differentiation, gene-expression responses and the regulation of proteins involved in connective-tissue models. These studies are intended to characterize biochemical activity under defined experimental conditions and should not be interpreted as evidence of therapeutic performance.

Its compact structure makes the compound relevant to research involving peptide transport, stability, receptor-independent signaling and sequence-specific cellular responses. Experimental outcomes may depend heavily on assay design, cell type, concentration and analytical preparation.

Cartalax in a 25 mg presentation. Because the Molecular Edge list specifies 25 mg, the concentration should be verified against inventory and the corresponding Certificate of Analysis before the page is published.

Research Specifications

Molecular Formula: C12H19N3O7

Molecular Weight: Approximately 317.30 g/mol

Amino Acid Count: 3

Sequence: Ala-Glu-Asp

Compound Type: Synthetic bioregulatory tripeptide

Molecular Edge Presentation: 25 mg

For Research Use Only. Not for human or animal consumption. Not intended for diagnostic or therapeutic use.